UTMB Allergy and Immunology: Research & Clinical Trials

Research is a central focus of UTMB’s Division of Allergy and Immunology. Since the creation of the division in the early 1970s, it has been one of the region's premier research-oriented allergy centers. Our research focuses on advancing the understanding of allergic and immunologic disorders, as well as improving measures for diagnosis and treatment. Clinical trials are carried out under strict guidelines with great attention to participant safety.

Individuals choose to participate in clinical research for many reasons. Some like the idea of being able to receive treatment with promising therapies before they are approved by the Food and Drug Administration for widespread commercial use. Others have tried conventional treatments and are in search of a new option. Still others may participate in clinical research in efforts to advance science and medicine.

We currently are conducting studies on hereditary angioedema, ACE inhibitor-induced angioedema, asthma, and immunodeficiencies. New studies are added frequently; call to check with us about our latest research and trials.

For more information about research studies and clinical trials, please contact Dr. Rana Bonds at (409) 772-3410.

Available Resources

UTMB Health is home to several unique facilities and programs that support clinical research and provide world class clinical and research opportunities.

Clinical Research Center

Child Health Research Center

Research Pharmacy

Aerospace Medicine Program

Affiliation with Shriners Burns Hospital

WHO Collaborating Center for Tropical Diseases

Institute for Translational Sciences
The ITS is the academic home of a five-year, $21.5 million Clinical Translational Sciences Award (CTSA) by the National Institutes of Health– National Center for Research Resources. The National CTSA Consortium, which currently includes 46 institutions, is working to improve human health by transforming the research and training environment to enhance the efficiency and quality of clinical and translational research.

NIH NHLBI Proteomics Center
UTMB is one of seven institutions which are part of a new proteomics program launched by the NHLBI on August 15, 2010. Collectively, the participating centers were awarded $83.5 million. UTMB has been a part of the NHLBI Proteomics Initiative since 2002. The new network consists of Boston University, Johns Hopkins University, Massachusetts General Hospital, Stanford University, the University of California-Los Angeles, the University of Texas Health Sciences Center at San Antonio, and UTMB Health.

Return to main page for Allergy and Immunology